Literature DB >> 26245676

Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma.

Janine C De Snoo-Trimp1, Linda Brom2, H Roeline W Pasman2, Bregje D Onwuteaka-Philipsen2, Guy A M Widdershoven2.   

Abstract

BACKGROUND: In cancer care, difficult decisions concerning advanced treatment need to be made, weighing possible life prolongation against harmful side effects. Treatment is frequently started, showing the need to explore how decisions are made. Little is known about the perspectives of physicians on sharing decision making with patients. This qualitative study aimed to describe the perspectives of medical specialists on the decision-making process with patients with glioblastoma concerning starting new treatment.
METHODS: Qualitative interviews were held with medical specialists. One focus group was organized with medical professionals. Their opinions about elements of shared decision making and the applicability in the context of patients with glioblastoma were assessed. The topic list for the focus group was based on the analysis of the interviews. Qualitative analysis of the transcripts was performed by three researchers independently.
RESULTS: Medical specialists considered shared decision making to be important; however, they did not adhere to its elements. Stopping treatment was not considered equal to continuing treatment. Exploration of the patients' wishes was done implicitly, and shared responsibility for the decision was not highly recognized. The main barriers to shared decision making were preferences of both patients and specialists for starting or continuing treatment and assumptions of physicians about knowing what patients want.
CONCLUSION: Medical specialists recognized the importance of patient involvement but experienced difficulty in sharing decision making in practice. Elements of shared decision making are partly followed but do not guide decision making. To improve cancer care, education of medical specialists and adjustment to the elements are needed to involve patients. ©AlphaMed Press.

Entities:  

Keywords:  End-of-life care; Glioblastoma; Medical ethics; Medical specialists; Qualitative research; Shared decision making

Mesh:

Year:  2015        PMID: 26245676      PMCID: PMC4591958          DOI: 10.1634/theoncologist.2015-0095

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  48 in total

1.  Early palliative care for patients with metastatic non-small-cell lung cancer.

Authors:  Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

2.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

Authors:  Michael Brada; Sally Stenning; Rhian Gabe; Lindsay C Thompson; David Levy; Roy Rampling; Sara Erridge; Frank Saran; Rao Gattamaneni; Kirsten Hopkins; Sarah Beall; V Peter Collins; Siow-Ming Lee
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

3.  Factors that affect the duration of the interval between the completion of palliative chemotherapy and death.

Authors:  Kenji Hashimoto; Kan Yonemori; Noriyuki Katsumata; Marika Hotchi; Tsutomu Kouno; Chikako Shimizu; Kenji Tamura; Masashi Ando; Masahiro Takeuchi; Yasuhiro Fujiwara
Journal:  Oncologist       Date:  2009-07-11

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 5.  Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review.

Authors:  J D Tariman; D L Berry; B Cochrane; A Doorenbos; K Schepp
Journal:  Ann Oncol       Date:  2009-11-25       Impact factor: 32.976

6.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

Authors:  Martin H Cohen; Yuan Li Shen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2009-11-06

7.  A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.

Authors:  Maria Grazia Fabrini; Giovanni Silvano; Ivan Lolli; Franco Perrone; Annarita Marsella; Valerio Scotti; Luca Cionini
Journal:  J Neurooncol       Date:  2008-11-19       Impact factor: 4.130

8.  Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Authors:  James R Perry; Philippe Rizek; Rosemary Cashman; Meredith Morrison; Tara Morrison
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

9.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration.

Authors:  A H Pieterse; M C M Baas-Thijssen; C A M Marijnen; A M Stiggelbout
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more
  1 in total

1.  Decisional needs of patients with recurrent high-grade glioma and their families.

Authors:  Helle Sorensen von Essen; Dawn Stacey; Karina Dahl Steffensen; Rikke Guldager; Frantz Rom Poulsen; Karin Piil
Journal:  Neurooncol Pract       Date:  2022-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.